Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
52.49
-0.33 (-0.62%)
Streaming Delayed Price
Updated: 12:37 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
Next >
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
April 17, 2024
Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
April 05, 2024
NASDAQ:INCY is showing good growth, while it is not too expensive.
Via
Chartmill
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
March 26, 2024
INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals.
Via
Chartmill
NASDAQ:INCY, a growth stock which is not overvalued.
March 15, 2024
Despite its growth, NASDAQ:INCY remains within the realm of affordability.
Via
Chartmill
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
March 12, 2024
Via
Benzinga
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
March 04, 2024
INCYTE CORP (NASDAQ:INCY): good value for what you're paying.
Via
Chartmill
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
February 14, 2024
Via
Benzinga
NASDAQ:INCY is not too expensive for the growth it is showing.
February 01, 2024
INCYTE CORP (NASDAQ:INCY) is not too expensive for the growth it is showing.
Via
Chartmill
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
March 11, 2024
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.
Via
InvestorPlace
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
March 07, 2024
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.
Via
InvestorPlace
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
February 26, 2024
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
Via
InvestorPlace
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
February 22, 2024
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering.
Via
Chartmill
Exit Now! 3 Biotech Stocks to Sell in February 2024
February 21, 2024
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.
Via
InvestorPlace
Expert Ratings for Incyte
December 13, 2023
Via
Benzinga
What's Up With Incyte Stock Lately?
December 12, 2023
Incyte Corporation (NASDAQ: INCY) shares are trading higher on Tuesday. The stock has risen rapidly since Monday.
Via
Benzinga
Earnings Scheduled For February 13, 2024
February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.
Via
Benzinga
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
February 12, 2024
INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
February 06, 2024
Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.
Via
Benzinga
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
February 05, 2024
Novartis will add to its cancer treatment pipeline with via the German biotech.
Via
Investor's Business Daily
Why Is MorphoSys (MOR) Stock Up 50% Today?
February 05, 2024
News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock.
Via
InvestorPlace
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
February 05, 2024
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold...
Via
Benzinga
NASDAQ:INCY is probably undervalued for the fundamentals it is displaying.
January 19, 2024
For those who appreciate value investing, INCYTE CORP (NASDAQ:INCY) is a compelling option with its solid fundamentals.
Via
Chartmill
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
January 18, 2024
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.
Via
InvestorPlace
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
January 10, 2024
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to
Via
Benzinga
In the world of growth stocks, NASDAQ:INCY shines as a value proposition.
January 10, 2024
Investors seeking growth at a reasonable cost should explore INCYTE CORP (NASDAQ:INCY).
Via
Chartmill
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
December 28, 2023
In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
NASDAQ:INCY is showing decent growth, but is still valued reasonably.
December 19, 2023
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering.
Via
Chartmill
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The 3 Most Undervalued Biotech Stocks to Buy in December
December 15, 2023
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.